Robert W. Baird Raises LivaNova (NASDAQ:LIVN) Price Target to $72.00

LivaNova (NASDAQ:LIVN) had its price target lifted by equities research analysts at Robert W. Baird from $66.00 to $72.00 in a report issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 40.82% from the stock’s current price.

A number of other brokerages have also weighed in on LIVN. The Goldman Sachs Group assumed coverage on shares of LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 price objective on the stock. Stifel Nicolaus upped their target price on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Needham & Company LLC raised their price target on shares of LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Finally, Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, LivaNova presently has a consensus rating of “Buy” and an average target price of $69.17.

LivaNova Stock Performance

LIVN opened at $51.13 on Thursday. The company has a market cap of $2.78 billion, a P/E ratio of 121.74 and a beta of 1.00. The company has a quick ratio of 2.94, a current ratio of 3.37 and a debt-to-equity ratio of 0.49. The firm’s 50-day moving average price is $51.13 and its 200-day moving average price is $53.12. LivaNova has a 52-week low of $42.75 and a 52-week high of $64.47.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.15. The business had revenue of $318.60 million for the quarter, compared to analyst estimates of $305.05 million. LivaNova had a net margin of 1.91% and a return on equity of 13.81%. As a group, equities analysts anticipate that LivaNova will post 2.58 EPS for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Hedge funds and other institutional investors have recently made changes to their positions in the company. Arizona State Retirement System grew its position in LivaNova by 2.0% during the second quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock valued at $828,000 after buying an additional 299 shares during the period. State of Michigan Retirement System boosted its stake in shares of LivaNova by 2.3% during the 1st quarter. State of Michigan Retirement System now owns 13,211 shares of the company’s stock worth $739,000 after acquiring an additional 300 shares in the last quarter. Atria Investments Inc grew its position in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after acquiring an additional 331 shares during the period. Fifth Third Bancorp increased its stake in shares of LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after purchasing an additional 332 shares in the last quarter. Finally, Hexagon Capital Partners LLC raised its holdings in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after purchasing an additional 370 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.